title: The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma.
abstract: OBJECTIVE
  To evaluate the short-term efficacy and safety of recombinant human endostatin (Endostar) combined with chemoradiotherapy for the treatment of advanced, locally recurrent nasopharyngeal carcinoma (NPC).
  
  
  METHODS
  Between March 2010 and October 2013, a total of 22 patients with stage rIII-IVb locally recurrent NPC underwent salvage radiotherapy with Endostar in Sun Yat-Sen University Cancer Center. Intensity-modulated radiotherapy (IMRT) was delivered. Platinum-based chemotherapy was used in a neoadjuvant protocol. Endostar was continuously administered intravenously (105 mg/m2) for 14 days (Days 1-14) from the first day of treatment during a 21-day cycle. Tumor response and treatment toxicities were observed.
  
  
  RESULTS
  Until January 2014, the median follow-up time was 13 months (range, 4-41 months). All patients completed the planned radiotherapy. A complete response was achieved in 20 patients, and a partial response was achieved in 2 patients. The incidence of grade 3-5 late radiation injury in this study was 50% (11/22) and that of nasopharyngeal mucosal necrosis was 31.8% (7/22).
  
  
  CONCLUSIONS
  Endostar combined with chemoradiotherapy may be effective in decreasing both the incidence of nasopharyngeal mucosal necrosis. Studies with a larger sample size and longer follow-up are warranted.
authors.affiliation: Department of Radiotherapy Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P. R. China.|Department of Radiation Oncology, Affiliated Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Guan
authors.affiliation: Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350009, P. R. China.
authors.forename: Anchuan
authors.initials: A
authors.lastname: Li
authors.affiliation: Department of Radiotherapy Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P. R. China.
authors.forename: Weiwei
authors.initials: W
authors.lastname: Xiao
authors.affiliation: Department of Radiotherapy Oncology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, P. R. China.
authors.forename: Shuai
authors.initials: S
authors.lastname: Liu
authors.affiliation: Department of Radiotherapy Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P. R. China.
authors.forename: Binbin
authors.initials: B
authors.lastname: Chen
authors.affiliation: Department of Radiotherapy Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P. R. China.
authors.forename: Taixiang
authors.initials: T
authors.lastname: Lu
authors.affiliation: Department of Radiotherapy Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P. R. China.
authors.forename: Chong
authors.initials: C
authors.lastname: Zhao
authors.affiliation: Department of Radiotherapy Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P. R. China.
authors.forename: Fei
authors.initials: F
authors.lastname: Han
mesh_terms: D000328:Adult; D059248:Chemoradiotherapy / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D043169:Endostatins / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009364:Neoplasm Recurrence, Local; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods; D011994:Recombinant Proteins / Q000008:administration & dosage*; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D016896:Treatment Outcome
chemical_list: D043169:Endostatins; D011994:Recombinant Proteins; D002945:Cisplatin
keywords: Endostar; chemotherapy; intensity-modulated radiotherapy; nasopharyngeal carcinoma; recurrence